MetaVia Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de MetaVia disminuyan en un 22.6% al año. Se prevé que el BPA aumente en un 41% al año.

Información clave

-22.6%

Tasa de crecimiento de los beneficios

41.03%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	25.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	31 Mar 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Artículo de análisis • Sep 17

We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Artículo de análisis • Oct 03

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Sep 29

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals (NASDAQ:NRBO) received Nasdaq notification indicating that the company has evidenced full compliance with the minimum bid price requirement As a result, the listing matter has been closed. Shares are trading up 4% premarket.

Artículo de análisis • Sep 14

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Sep 12

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares are surging 56% on announcing a 1-for-30 reverse split of its common stock, par value $0.001. The trading on a split adjusted basis will commence on Nasdaq from September 13, 2022. The number of authorized shares of the company's common stock will remain at 100M, while the number of outstanding shares will be reduced from ~26.7M to ~0.9M.

Seeking Alpha • Nov 25

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

NeuroBo Pharmaceuticals is advancing novel disease-modifying therapies for viral, neuropathic and neurodegenerative diseases. The Company has four candidates in the development pipeline, with the lead candidate ANA001 being advanced for treatment of moderate COVID-19. The Company seeks an EUA for the lead candidate, failing which it intends to pursue an NDA via a 505(b)(2) pathway.

Artículo de análisis • Dec 21

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

If you want to know who really controls NeuroBo Pharmaceuticals, Inc. ( NASDAQ:NRBO ), then you'll have to look at the...

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:MTVA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2028	N/A	-33	N/A	N/A	3
12/31/2027	N/A	-28	N/A	N/A	3
12/31/2026	N/A	-18	N/A	N/A	3
12/31/2025	N/A	-13	-16	-16	N/A
9/30/2025	N/A	-16	-16	-16	N/A
6/30/2025	N/A	-18	-19	-19	N/A
3/31/2025	N/A	-25	-23	-23	N/A
12/31/2024	N/A	-28	-25	-25	N/A
9/30/2024	N/A	-28	-23	-23	N/A
6/30/2024	N/A	-26	-20	-20	N/A
3/31/2024	N/A	-17	-15	-15	N/A
12/31/2023	N/A	-12	-11	-11	N/A
9/30/2023	N/A	-12	-9	-9	N/A
6/30/2023	N/A	-11	-9	-9	N/A
3/31/2023	N/A	-14	-9	-9	N/A
12/31/2022	N/A	-14	-12	-12	N/A
9/30/2022	N/A	-14	-13	-13	N/A
6/30/2022	N/A	-14	-13	-13	N/A
3/31/2022	N/A	-15	-14	-14	N/A
12/31/2021	N/A	-15	-15	-15	N/A
9/30/2021	N/A	-30	-15	-15	N/A
6/30/2021	N/A	-30	-14	-14	N/A
3/31/2021	N/A	-28	-13	-13	N/A
12/31/2020	N/A	-30	-11	-11	N/A
9/30/2020	N/A	-23	-10	-10	N/A
6/30/2020	N/A	-24	-11	-11	N/A
3/31/2020	N/A	-24	-10	-10	N/A
12/31/2019	N/A	-21	-7	-7	N/A
9/30/2019	N/A	-12	N/A	-10	N/A
6/30/2019	N/A	-11	N/A	-9	N/A
3/31/2019	N/A	-13	N/A	-12	N/A
12/31/2018	N/A	-16	N/A	-14	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MTVA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que MTVA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que MTVA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de MTVA crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que MTVA no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MTVA se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/05/14 10:33
Precio de las acciones al final del día	2026/05/14 00:00
Beneficios	2025/12/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

MetaVia Inc. está cubierta por 3 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Andrew Fein	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group
David Bautz	Zacks Small-Cap Research

MetaVia Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 16% to US$132

Price target increased by 40% to US$20.00

Price target decreased by 7.5% to US$14.33

Price target decreased by 35% to US$17.33

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

MetaVia Inc., Annual General Meeting, Jun 08, 2026

Metavia Inc Doses First Patient in Higher-Dose Phase 1 Study of Da-1726

Metavia Inc. Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726

MetaVia Inc Expands Global Patent Protection For Vanoglipel Supporting Metabolic And Liver Disease Therapy Through 2035

MetaVia Inc. Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

MetaVia Inc. has completed a Composite Units Offering in the amount of $8.099988 million.

Metavia Inc. Reports Positive Statistically Significant Results from Its Phase 1B Clinical Trial of DA-1726 in Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Price target decreased by 16% to US$132

Nasdaq Grants Extension to MetaVia Inc. to Regain Minimum Bid Price Compliance

MetaVia Inc. Presents Positive New Phase 2A Data on Vanoglipel (Da-1241) in Patients with Presumed Mash At the Aasld the Liver Meeting®? 2025

We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate

Price target increased by 40% to US$20.00

New major risk - Financial position

MetaVia Inc. Extends 48 Mg Mad Portion of Its Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

MetaVia Inc. Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

MetaVia Inc. Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination with Efruxifermin at the ADA's 85th Scientific Session

MetaVia Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

MetaVia Inc., Annual General Meeting, Jun 30, 2025

Price target decreased by 7.5% to US$14.33

MetaVia Inc. announced that it has received $9.995395 million in funding

MetaVia Inc. announced that it expects to receive $9.995395 million in funding

Metavia Inc. Presents Data on DA-1241, GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed Mash, at the EASL Congress 2025

MetaVia Inc. Reports Additional Positive Top-Line Results from the MAD Part 2 of Its Phase 1 Study of DA-1726

New major risk - Market cap size

MetaVia Inc. Announces Clinical Trials

Price target decreased by 35% to US$17.33

MetaVia Inc. Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

New major risk - Financial position

NeuroBo Pharmaceuticals, Inc. Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Neurobo Pharmaceuticals Announces Positive Top-Line Data from the Sad Part 1 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.000001 million.

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment

Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of Nash

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals Receives 180-Day Extension to February 5, 2024 from Nasdaq to Regain Compliance with the Minimum Bid Price Requirement

Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Neurobo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to Its Board of Directors

NeuroBo Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

NeuroBo Pharmaceuticals, Inc. Appoints Joseph Hooker as President

NeuroBo Pharmaceuticals, Inc. announced that it has received $15 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals Compliant with All Applicable Nasdaq Listing Criteria

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $37 million in funding from Dong-A ST Co., Ltd.

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Neurobo Pharmaceuticals, Inc. Appoints Matthew Bardin as Senior Vice President Operations

High number of new and inexperienced directors

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

No longer forecast to breakeven

Independent Director Jeong Gyun Oh has left the company

No longer forecast to breakeven

Price target decreased to US$16.00

NeuroBo Pharmaceuticals, Inc.(NasdaqCM:NRBO) dropped from Russell 3000E Index